M. Rui

发表

Economic Evaluation of Cisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine for the Treatment of First-Line Advanced Metastatic Triple-Negative Breast Cancer in China: Using Markov Model and Partitioned Survival Model

Hongchao Li, M. Rui, Fenghao Shi, 2020, Advances in Therapy.

The Relationship Between Short-Term Surrogate Endpoint Indicators and mPFS and mOS in Clinical Trials of Malignant Tumors: A Case Study of Approved Molecular Targeted Drugs for Non-Small-Cell Lung Cancer in China

Hongchao Li, M. Rui, Y. Shang, 2022, Frontiers in Pharmacology.

Will the Inducing and Maintaining Remission of Non-biological Agents and Biological Agents Differ for Crohn's Disease? The Evidence From the Network Meta-Analysis

Hongchao Li, A. Ma, M. Rui, 2021, Frontiers in Medicine.

Cost-effectiveness analysis of sintilimab + chemotherapy versus camrelizumab + chemotherapy for the treatment of first-line locally advanced or metastatic nonsquamous NSCLC in China

Hongchao Li, A. Ma, M. Rui, 2022, Journal of medical economics.

Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell Lung Cancer in the US

Hongchao Li, A. Ma, M. Rui, 2021, Frontiers in Public Health.

Will the Markov model and partitioned survival model lead to different results? A review of recent economic evidence of cancer treatments

Hongchao Li, M. Rui, Y. Shang, 2021, Expert review of pharmacoeconomics & outcomes research.

Cost-effectiveness of anlotinib vs. pembrolizumab and nivolumab as third-line treatment in recurrent small cell lung cancer in China

A. Ma, M. Rui, Yingcheng Wang, 2022, Expert review of pharmacoeconomics & outcomes research.

Economic Evaluation of Rituximab + Recombinant Human Thrombopoietin vs. Rituximab for the Treatment of Second-Line Idiopathic Thrombocytopenic Purpura in China

Hongchao Li, A. Ma, M. Rui, 2021, Frontiers in Medicine.

Cost-Effectiveness Analysis of Abemaciclib Plus Fulvestrant in the Second-Line Treatment of Women With HR+/HER2– Advanced or Metastatic Breast Cancer: A US Payer Perspective

M. Rui, Yingcheng Wang, X. Guan, 2021, Frontiers in Medicine.

Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC

Hongchao Li, A. Ma, M. Rui, 2022, Frontiers in Public Health.

Health-Related Quality of Life in Patients With Different Diseases Measured With the EQ-5D-5L: A Systematic Review

M. Rui, Aixia Ma, Luying Wang, 2021, Frontiers in Public Health.

Cost-effectiveness of Osimertinib vs Docetaxel-Bevacizumab in Third-Line Treatment in EGFR T790M Resistance Mutation Advanced Non-Small Cell Lung Cancer in China.

Hongchao Li, M. Rui, 2020, Clinical therapeutics.

Immunotherapy Guided by Immunohistochemistry PD-L1 Testing for Patients with NSCLC: A Microsimulation Model-Based Effectiveness and Cost-Effectiveness Analysis

M. Rui, Z. Fei, Yingcheng Wang, 2023, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.